HCG Levels After Ovulation Triggering as Predictors of ICSI Outcome
NCT ID: NCT05969834
Last Updated: 2023-08-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2021-03-31
2022-08-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dual Trigger Versus GnRHa Trigger Combined With Luteal HCG Administration
NCT02330770
Timing of HCG Administration in IUI Cycles
NCT02330705
Intrauterine Injection of Human Chorionic Gonadotropin Before Embryo Transfer in Women With Previous IVF Failure
NCT02329197
Administration of Human Chorionic Gonadotrophin Before Secretory Transformation of Frozen-thawed Embryo Transfer Cycles
NCT05340010
Intra-uterine Injection of Human Chorionic Gonadotrophin (hCG) Before Embryo Transfer
NCT01030393
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. To assess the correlation between serum human chorionic gonadotropin (hCG) level after ovulation triggering and intracytoplasmic sperm injection (ICSI) outcome including: oocyte maturity and quality, good quality embryo rate, blastocyst formation rate and pregnancy rate
2. To determine if there is an association between type and dose of the trigger and ICSI outcome.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
uHCG group
Trigger intramuscular (IM) administration of 10000 IU of uHCG
uHCG
Final oocyte maturation will be triggered by IM administration of 10000 IU of uHCG (Choriomon)
rHCG group
Trigger with subcutaneous (SC) administration of 6500 IU of rHCG
rHCG
Final oocyte maturation will be triggered by SC administration of 6500 IU of rHCG (Ovitrelle)
Dual trigger group
Combined SC administration of 0.1 mg of GnRHa and IM administration of 2500 IU of uHCG
uHCG and GnRHa
Final oocyte maturation will be triggered by combined SC administration of 0.1 mg of GnRHa (Decapeptyl, Triptorelin) and IM administration of 2500 IU of uHCG (Choriomon)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
uHCG
Final oocyte maturation will be triggered by IM administration of 10000 IU of uHCG (Choriomon)
rHCG
Final oocyte maturation will be triggered by SC administration of 6500 IU of rHCG (Ovitrelle)
uHCG and GnRHa
Final oocyte maturation will be triggered by combined SC administration of 0.1 mg of GnRHa (Decapeptyl, Triptorelin) and IM administration of 2500 IU of uHCG (Choriomon)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Irregular menstruation
* Severe male factor abnormality
* Poor ovarian reserve
* Endometriosis
* Uterine abnormality
18 Years
35 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mansoura University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Engy Abdallah, MSc
Role: PRINCIPAL_INVESTIGATOR
Mansoura University
Mohamed S Abdelhafez, MD
Role: STUDY_DIRECTOR
Mansoura University
Mohamed Elzayat, MD
Role: STUDY_CHAIR
Royal Center
Amoura Abou-ElNaga, MD
Role: STUDY_CHAIR
Mansoura University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal Center
Al Mansurah, Dakahlia Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MD.20.09.370
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.